Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Allergy Immunotherapy

Yudy Persaud  1 , Ruba J. Memon  2 , Mohammedi N. Savliwala  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Allergy Immunotherapy

Yudy Persaud et al.
Free Books & Documents

Excerpt

Allergy immunotherapy (AIT), also referred to as allergen desensitization or hypo-sensitization was first introduced by Leonard Noon and John Freeman in 1911, they proposed that people with hay fever were sensitive to grass pollen toxins. Noon is credited for developing a process involved in the extraction of timothy pollen in distilled water and then boiling it to create an extract. This extract was then injected in increasing doses to alleviate symptoms in patients. This concept is widely in use today with a modified approach. Currently, the term immunotherapy is used to describe all methods to overcome abnormal immune responses with induction of clonal deletion, anergy, immune tolerance, and immune deviation. However, the term desensitization is "a method, to develop a temporary state of tolerance to an agent responsible for an allergic or hypersensitivity reaction." Furthermore, immunotherapy is a disease-modifying treatment and the effects can last longer even after stopping the treatment, which then provides prophylactic effects.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Yudy Persaud declares no relevant financial relationships with ineligible companies.

Disclosure: Ruba Memon declares no relevant financial relationships with ineligible companies.

Disclosure: Mohammedi Savliwala declares no relevant financial relationships with ineligible companies.

References

    1. NOON L. Prophylactic inoculation against hay fever (historical document). Ann Allergy. 1955 Nov-Dec;13(6):713-6; passim. - PubMed
    1. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55. - PubMed
    1. Tanno LK, Calderon MA, Papadopoulos NG, Sanchez-Borges M, Rosenwasser LJ, Bousquet J, Pawankar R, Sisul JC, Cepeda AM, Li J, Muraro A, Fineman S, Sublett JL, Katelaris CH, Chang YS, Moon HB, Casale T, Demoly P, Joint Allergy Academies Revisiting Desensitization and Allergen Immunotherapy Concepts for the International Classification of Diseases (ICD)-11. J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):643-9. - PubMed
    1. Halken S, Larenas-Linnemann D, Roberts G, Calderón MA, Angier E, Pfaar O, Ryan D, Agache I, Ansotegui IJ, Arasi S, Du Toit G, Fernandez-Rivas M, Geerth van Wijk R, Jutel M, Kleine-Tebbe J, Lau S, Matricardi PM, Pajno GB, Papadopoulos NG, Penagos M, Santos AF, Sturm GJ, Timmermans F, van Ree R, Varga EM, Wahn U, Kristiansen M, Dhami S, Sheikh A, Muraro A. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017 Dec;28(8):728-745. - PubMed
    1. Di Lorenzo G, Leto-Barone MS, La Piana S, Plaia A, Di Bona D. The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis. Int Forum Allergy Rhinol. 2017 Jul;7(7):660-669. - PubMed

Publication types

LinkOut - more resources